Perineural invasion predicts for locoregional failure in patients with oesophageal adenocarcinoma treated with neoadjuvant chemoradiotherapy
- 21 April 2020
- journal article
- research article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 74 (4), 228-233
- https://doi.org/10.1136/jclinpath-2020-206424
Abstract
Aim The prognostic significance of perineural invasion (PNI) in oesophageal adenocarcinoma (EAC) is unclear. We examined the association of PNI with clinical outcomes in patients treated with neoadjuvant chemoradiotherapy (nCRT) and surgery. Methods We performed a single institutional retrospective study. We evaluated the association of PNI with locoregional recurrence-free survival (LRFS), distant metastasis-free survival, disease-free survival (DFS) and overall survival using log-rank and Cox proportional hazard modelling. Results 29 out of 73 patients (40%) had PNI at the time of surgery. The median follow-up was 20.1 months. The median DFS was 18.4 months for patients with PNI vs 41.3 months for patients without PNI (pConclusions For patients with EAC treated with nCRT, PNI found at the time of surgery is significantly associated with worse LRFS. Our data support attempts to validate this finding and perhaps testing the role of adjuvant therapy in patients with PNI.Keywords
This publication has 19 references indexed in Scilit:
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- The prognostic effect of perineural invasion in esophageal squamous cell carcinomaBMC Cancer, 2014
- Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagusWorld Journal of Gastroenterology, 2013
- Preoperative Chemoradiotherapy for Esophageal or Junctional CancerThe New England Journal of Medicine, 2012
- Esophageal cancer—the five year survivorsJournal of Surgical Oncology, 2010
- Perineural invasion in cancerCancer, 2009
- Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781Journal of Clinical Oncology, 2008
- Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysisThe Lancet Oncology, 2007
- Pathological determinants of survival in node-negative oesophageal cancerBritish Journal of Surgery, 2004
- Surgical Pathology of Adenocarcinoma Arising in Barrettʼs Esophagus Analysis of 67 CasesThe American Journal of Surgical Pathology, 1995